10 December 2024
Tingwang Shi, Qiong Wu, Zesong Ruan, Zhiyuan Luo, Wenbo Wang, Zhao Guo, Yihong Ma, Xin Wang, Guangyu Chu, Han Lin, Min Ge, Yunfeng Chen
The cover of this issue of Advanced Science is "Resensitizing β-Lactams by Reprogramming Purine Metabolism in Small Colony Variant for Osteomyelitis Treatment" published by Professor Chen Yunfeng from the Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine and Dr. Ge Min from the University of Hong Kong.
Research background
Small colony variant (SCV) is a special bacterial subgroup that is closely related to the persistence of antibiotic resistance and osteomyelitis. However, the intrinsic phenotypic instability of SCV has always hindered the in-depth study of its pathogenic mechanism. This instability of SCV makes it difficult for scientists to stably study its characteristics under laboratory conditions, thus limiting the comprehensive understanding of its resistance and pathogenicity.
Research significance
This study successfully isolated phenotypically stable SCV strains from clinical specimens, providing stable experimental materials for in-depth study of the pathogenic mechanism and drug resistance of SCV. Through multi-omics analysis, the study found that the high drug resistance of SCV is related to changes in its purine metabolic pathway, especially due to mutations in the hypoxanthine phosphoribosyltransferase (hpt) gene. This finding provides a new perspective for understanding the drug resistance mechanism of SCV.
This study innovatively found that lonidamine, an inhibitor of cellular energy metabolism, can effectively reduce SCV's resistance to β-lactam antibiotics, thereby contributing to its eradication. This discovery provides a new therapeutic strategy for the treatment of SCV-related diseases. A co-delivery system of londamin and oxacillin with amino-modified dendritic mesoporous silica as carrier was also constructed. The system showed high efficacy and safety in both in vitro and in vivo experiments, providing strong support for clinical application.
Research Prospects
Future studies can further explore how hpt gene mutations affect the purine metabolic pathway and how this metabolic change leads to increased SCV resistance. At the same time, it can also be studied how londamin can alleviate SCV resistance by reprogramming purine metabolism. In addition to osteomyelitis, SCV is also associated with a variety of infectious diseases. Future studies can explore the application of this treatment strategy in the treatment of other SCV-related infectious diseases. Based on a deeper understanding of the current mechanism, new drugs or therapies targeting SCV resistance can be developed to more effectively treat SCV-related diseases.
Cover Design Process
ساعات عملنا
الإثنين 21/11 - الأربعاء 23/11: 9 صباحًا - 8 مساءً
الخميس 24/11: مغلق - عيد شكر سعيد!
الجمعة 25/11: 8 صباحًا - 10 مساءً
السبت 26/11 - الأحد 27/11: 10 صباحًا - 9 مساءً
(جميع الساعات بالتوقيت الشرقي)